Priorities in Cardio-Oncology Basic and Translational Science: GCOS 2023 Symposium Proceedings: State-of-the-Art Review

Despite improvements in cancer survival, cancer therapy-related cardiovascular toxicity has risen to become a prominent clinical challenge. This has led to the growth of the burgeoning field of cardio-oncology, which aims to advance the cardiovascular health of cancer patients and survivors, through actionable and translatable science. In these Global Cardio-Oncology Symposium 2023 scientific symposium proceedings, we present a focused review on the mechanisms that contribute to common cardiovascular toxicities discussed at this meeting, the ongoing international collaborative efforts to improve patient outcomes, and the bidirectional challenges of translating basic research to clinical care. We acknowledge that there are many additional therapies that are of significance but were not topics of discussion at this symposium. We hope that through this symposium-based review we can highlight the knowledge gaps and clinical priorities to inform the design of future studies that aim to prevent and mitigate cardiovascular disease in cancer patients and survivors.

Citing Articles

Immune-checkpoint-inhibitor therapy directed against PD-L1 is tolerated in the heart without manifestation of cardiac inflammation in a preclinical reversible melanoma mouse model.

Schoenherr C, Pietzsch S, Barca C, Muller F, Bahr F, Kasten M Front Mol Med. 2025; 4():1487526.

PMID: 39834851 PMC: 11743445. DOI: 10.3389/fmmed.2024.1487526.

SGLT2i and Primary Prevention of Cancer Therapy-Related Cardiac Dysfunction in Patients With Diabetes.

Bhatti A, Patel R, Dani S, Khadke S, Makwana B, Lessey C JACC CardioOncol. 2025; 6(6):863-875.

PMID: 39801650 PMC: 11711834. DOI: 10.1016/j.jaccao.2024.08.001.

Role of Cancer History in Cardiovascular Mortality Among Different Age-group Patients With Differentiated Thyroid Cancer.

Qiu H, Zhou W, Huang Q, Lin H, Zhou Y, Wu C J Endocr Soc. 2024; 9(1):bvae213.

PMID: 39669653 PMC: 11635452. DOI: 10.1210/jendso/bvae213.

The cardio-oncologic burden of breast cancer: molecular mechanisms and importance of preclinical models.

Brauer J, Tumani M, Frey N, Lehmann L Basic Res Cardiol. 2024; 120(1):91-112.

PMID: 39621070 PMC: 11790711. DOI: 10.1007/s00395-024-01090-w.

Anthracycline Cardiotoxicity in Adult Cancer Patients: State-of-the-Art Review.

Camilli M, Cipolla C, Dent S, Minotti G, Cardinale D JACC CardioOncol. 2024; 6(5):655-677.

PMID: 39479333 PMC: 11520218. DOI: 10.1016/j.jaccao.2024.07.016.

References

Koelwyn G, Aboumsallem J, Moore K, de Boer R . Reverse cardio-oncology: Exploring the effects of cardiovascular disease on cancer pathogenesis. J Mol Cell Cardiol. 2021; 163:1-8. PMC: 8816816. DOI: 10.1016/j.yjmcc.2021.09.008. View

Ehrhardt M, Leerink J, Mulder R, Mavinkurve-Groothuis A, Kok W, Nohria A . Systematic review and updated recommendations for cardiomyopathy surveillance for survivors of childhood, adolescent, and young adult cancer from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncol. 2023; 24(3):e108-e120. DOI: 10.1016/S1470-2045(23)00012-8. View

Porta-Sanchez A, Gilbert C, Spears D, Amir E, Chan J, Nanthakumar K . Incidence, Diagnosis, and Management of QT Prolongation Induced by Cancer Therapies: A Systematic Review. J Am Heart Assoc. 2017; 6(12). PMC: 5779062. DOI: 10.1161/JAHA.117.007724. View

Meijers W, Maglione M, Bakker S, Oberhuber R, Kieneker L, de Jong S . Heart Failure Stimulates Tumor Growth by Circulating Factors. Circulation. 2018; 138(7):678-691. DOI: 10.1161/CIRCULATIONAHA.117.030816. View

Meijers W, de Boer R . Common risk factors for heart failure and cancer. Cardiovasc Res. 2019; 115(5):844-853. PMC: 6452432. DOI: 10.1093/cvr/cvz035. View

Moslehi J, Salem J, Sosman J, Lebrun-Vignes B, Johnson D . Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet. 2018; 391(10124):933. PMC: 6668330. DOI: 10.1016/S0140-6736(18)30533-6. View

Fazal M, Malisa J, Rhee J, Witteles R, Rodriguez F . Racial and Ethnic Disparities in Cardio-Oncology: A Call to Action. JACC CardioOncol. 2021; 3(2):201-204. PMC: 8301207. DOI: 10.1016/j.jaccao.2021.05.001. View

Alexandre J, Salem J, Moslehi J, Sassier M, Ropert C, Cautela J . Identification of anticancer drugs associated with atrial fibrillation: analysis of the WHO pharmacovigilance database. Eur Heart J Cardiovasc Pharmacother. 2020; 7(4):312-320. DOI: 10.1093/ehjcvp/pvaa037. View

Fradley M, Beckie T, Brown S, Cheng R, Dent S, Nohria A . Recognition, Prevention, and Management of Arrhythmias and Autonomic Disorders in Cardio-Oncology: A Scientific Statement From the American Heart Association. Circulation. 2021; 144(3):e41-e55. PMC: 8992663. DOI: 10.1161/CIR.0000000000000986. View

10.

Guha A, Derbala M, Zhao Q, Wiczer T, Woyach J, Byrd J . Ventricular Arrhythmias Following Ibrutinib Initiation for Lymphoid Malignancies. J Am Coll Cardiol. 2018; 72(6):697-698. PMC: 7529121. DOI: 10.1016/j.jacc.2018.06.002. View

11.

Huang C, Zhang X, Ramil J, Rikka S, Kim L, Lee Y . Juvenile exposure to anthracyclines impairs cardiac progenitor cell function and vascularization resulting in greater susceptibility to stress-induced myocardial injury in adult mice. Circulation. 2010; 121(5):675-83. PMC: 2834271. DOI: 10.1161/CIRCULATIONAHA.109.902221. View

12.

Mondal P, Jain D, Aronow W, Frishman W . Cardiotoxicity of Cancer Therapies. Cardiol Rev. 2018; 27(5):230-235. DOI: 10.1097/CRD.0000000000000239. View

13.

Laursen A, Elming M, Ripa R, Hasbak P, Kjaer A, Kober L . Rubidium-82 positron emission tomography for detection of acute doxorubicin-induced cardiac effects in lymphoma patients. J Nucl Cardiol. 2018; 27(5):1698-1707. DOI: 10.1007/s12350-018-1458-6. View

14.

Steensma D, Bolton K . What to tell your patient with clonal hematopoiesis and why: insights from 2 specialized clinics. Blood. 2020; 136(14):1623-1631. PMC: 7530645. DOI: 10.1182/blood.2019004291. View

15.

Coombs C, Zehir A, Devlin S, Kishtagari A, Syed A, Jonsson P . Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes. Cell Stem Cell. 2017; 21(3):374-382.e4. PMC: 5591073. DOI: 10.1016/j.stem.2017.07.010. View

16.

Wang X, Singh P, Zhou L, Sharafeldin N, Landier W, Hageman L . Genome-Wide Association Study Identifies as a Novel Susceptibility Gene for Anthracycline-Related Cardiomyopathy in Childhood Cancer Survivors. J Clin Oncol. 2022; 41(9):1758-1769. PMC: 10043563. DOI: 10.1200/JCO.22.01527. View

17.

Cardinale D, Iacopo F, Cipolla C . Cardiotoxicity of Anthracyclines. Front Cardiovasc Med. 2020; 7:26. PMC: 7093379. DOI: 10.3389/fcvm.2020.00026. View

18.

Fendly B, Winget M, Hudziak R, Lipari M, Napier M, Ullrich A . Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. Cancer Res. 1990; 50(5):1550-8. View

19.

Todorova V, Wei J, Makhoul I . Subclinical doxorubicin-induced cardiotoxicity update: role of neutrophils and endothelium. Am J Cancer Res. 2021; 11(9):4070-4091. PMC: 8493405. View

20.

Livingston C, Ky B, Margulies K . How to Apply Translational Models to Probe Mechanisms of Cardiotoxicity. JACC CardioOncol. 2022; 4(1):130-135. PMC: 9040120. DOI: 10.1016/j.jaccao.2022.01.097. View